IVERIC bio, Inc. (ISEE) News
Filter ISEE News Items
ISEE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ISEE News Highlights
- ISEE's 30 day story count now stands at 2.
- Over the past 6 days, the trend for ISEE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and TSE are the most mentioned tickers in articles about ISEE.
Latest ISEE News From Around the Web
Below are the latest news stories about IVERIC BIO INC that investors may wish to consider to help them evaluate ISEE as an investment opportunity.
Astellas Completes Acquisition of Iveric BioAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary. |
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PARSIPPANY, N.J., July 05, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees. |
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's WhyAnnexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy. |
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas PharmaAstellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. |
These Stocks Moved the Most Today: First Republic, JPMorgan, Iveric Bio, SoFi, Norwegian Cruise, ON Semi, and MoreJPMorgan Chase is acquiring all the deposits and 'substantially all of the assets' of regional lender First Republic Bank. Iveric Bio is being bought by Japan's Astellas Pharma for $5.9 billion. |
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top StoriesBenzinga First Republic Folds As Banking Crisis Claims Third Victim: JPMorgan To Buy Deposits, Assets The First Republic Bank (NYSE: FRC) saga is winding to a close, with the Federal Deposit Insurance Corporation confirming the shuttering of the bank and the sale of its assets to JPMorgan Chase & Co. (NYSE: JPM). The California Department of Financial Protection and Innovation closed San Francisco-based First Republic on Monday. The FDIC was appointed receiver, a statement released by the federa |
These Stocks Are Moving the Most Today: First Republic, JPMorgan, Iveric Bio, SoFi, ON Semi, and MoreCARD JPMorgan Chase is acquiring all the deposits and 'substantially all of the assets' of regional lender First Republic Bank, the FDIC says. Iveric Bio is being bought by Japan's Astellas Pharma for $5. |
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of approximately $5.9 billion. Iveric Bio focuses on discovering and developing novel treatments in the field of ophthalmology. Astellas expects the deal to advance its primary focus on "Blindness & Regeneration." Related: IVERIC Bio's Geographic Atrophy Candidate Shows Significant Reduction In Disease Progression. The company announce |
Iveric Bio Agrees to $5.9 Billion Bid From Astellas. Buyers Are Hunting Biopharma Bargains.Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs. |
UPDATE 1-Japan's Astellas Pharma agrees to buy IVERIC Bio for $5.9 blnJapan's Astellas Pharma said on Monday it agreed to buy U.S.-based drugmaker IVERIC Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. Through Berry Merger Sub Inc, a wholly-owned subsidiary of Astellas U.S. Holding, the Japanese company agreed to acquire IVERIC for $40 per share in cash, Astellas said in a release. The acquisition price is a 22% premium to IVERIC's $32.89 closing price on April 28. |